Indaptus Therapeutics, Inc. INDP

Indaptus Therapeutics, Inc. (INDP) reported first quarter 2026 financial results and provided a corporate update. Quarterly financial results and corporate updates affect financial performance and investor sentiment for biotech firms like INDP.

Indaptus Therapeutics, Inc. has entered into a $6 million securities purchase agreement with investor David E. Lazar. This agreement is expected to provide the company with additional capital to support its operations and development initiatives. The agreement provides necessary funding that may influence the company's operational capabilities and market sentiment.

Indaptus Therapeutics, Inc. (INDP) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect recent developments or market sentiment surrounding the company's operations and future prospects. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

Dr. Michael Newman, Chief Scientific Officer of Indaptus Therapeutics, Inc. (INDP), is scheduled to present at the Donor Selection & Cell Source Summit. The event will focus on advancements in donor selection and cell sourcing, which are critical areas for the development of innovative therapies. Newman's participation highlights the company's commitment to advancing its scientific initiatives and engaging with industry leaders. Participation in industry summits can enhance networking and collaboration opportunities, potentially influencing product innovation.

Indaptus Therapeutics, Inc. (INDP) reported its financial results for the third quarter of 2025, highlighting key developments in its corporate strategy and financial performance. The company provided updates on ongoing clinical trials and future plans, emphasizing its commitment to advancing its therapeutic pipeline. Financial metrics showed progress, with notable changes in revenue and expenditures compared to previous quarters. The financial results and corporate updates indicate moderate progress in key areas that may influence future performance.

Indaptus Therapeutics, Inc. (INDP) reports third quarter 2024 financial results and provides corporate update. The financial results and corporate update may moderately influence key areas such as financial performance and competitive positioning.

Indaptus Therapeutics, Inc. provided a clinical update on its ongoing trials, highlighting progress in its therapeutic programs and upcoming milestones. The company reported positive preliminary results from its studies, indicating potential advancements in treatment efficacy. Additionally, management outlined future plans for further clinical evaluations and collaborations aimed at enhancing product development. Positive preliminary results and future clinical plans are likely to significantly impact the company's trajectory and investor sentiment.

Indaptus Therapeutics, Inc. (INDP) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, where the company will present its latest developments and strategic initiatives. This event provides a platform for the company to engage with investors and showcase its growth potential in the biotechnology sector. Participation in a significant investment conference may enhance investor interest and market visibility, but the overall impact on the company's trajectory is expected to be limited.

Indaptus Therapeutics, Inc. reported its financial results for the second quarter of 2025, highlighting key metrics and developments in its corporate strategy. The company provided updates on ongoing projects and future plans, indicating a focus on advancing its therapeutic pipeline and enhancing shareholder value. The financial results and corporate updates suggest a moderate influence on the company's performance and market sentiment.

Indaptus Therapeutics, Inc. has announced the sale of $3.4 million in a private placement of convertible notes and warrants. This financing aims to support the company's ongoing development efforts and operational needs. The financing could provide necessary capital for development, impacting financial performance moderately.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced a one-for-twenty-eight reverse stock split effective after trading on June 26, 2025. The split aims to increase the per share price and comply with Nasdaq listing requirements, making the stock more appealing to institutional investors. Post-split, approximately 16 million shares will reduce to about 572 thousand. Stockholders will receive cash for any fractional shares. The company’s common stock will continue to trade under the symbol 'INDP' on a split-adjusted basis. The reverse stock split is a strategic move to comply with Nasdaq requirements and potentially attract institutional investors, impacting market perception.

Indaptus Therapeutics, Inc. announced the sale of approximately $2.3 million in convertible promissory notes and warrants, aiming to raise up to $5 million in total. The notes carry a 6% interest rate and will mature on July 28, 2026, converting into common stock at a price equal to 80% of the average Nasdaq closing price, with a maximum price of $0.40. Warrants for 200% of the conversion shares will be issued post-conversion, pending stockholder approval. Proceeds will fund research and development, including a Phase 1b/2 clinical trial. The offering is conducted under private placement regulations and has not been registered under the Securities Act. The funding will support critical clinical trials and research, significantly impacting the company's future performance and market position.

Indaptus Therapeutics, Inc. has dosed its first patient in a Phase 1b/2 clinical trial evaluating Decoy20 in combination with the PD-1 checkpoint inhibitor tislelizumab for advanced solid tumors. This trial aims to assess safety, dosing, and preliminary anti-tumor activity in patients previously treated with checkpoint inhibitors or those with tumors typically unresponsive to such therapies. CEO Jeffrey Meckler highlighted the potential of the Decoy platform to enhance immune responses in patients who have not benefited from existing treatments. The combination therapy has shown promise in preclinical studies, and over 25 patients have already received Decoy20 with manageable side effects. The initiation of this combination trial represents a significant strategic move that could enhance treatment options for patients with advanced solid tumors, potentially altering the company's trajectory.

Indaptus Therapeutics, Inc. (INDP) reported its financial results for the first quarter of 2025, highlighting key metrics and developments in its corporate strategy. The company provided updates on its ongoing projects and future plans, emphasizing its commitment to advancing its therapeutic pipeline. Financial performance indicators showed trends that may influence investor sentiment and operational focus moving forward. The financial results and corporate updates indicate moderate influences on the company's performance and market positioning.

Dr. Michael Newman, Founder and Chief Scientific Officer of Indaptus Therapeutics, has been appointed as Chair and Expert Speaker at the 6th Annual Cytokine-Based Drug Development Summit. This recognition highlights his expertise in cytokine-based therapies and underscores the company's commitment to advancing innovative treatments in this field. Newman's appointment as Chair at a significant summit may enhance the company's visibility and influence in cytokine-based drug development.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) announces that Chief Medical Officer Roger Waltzman, M.D., M.B.A. will moderate a panel at the CMO360 Summit on April 7-8 in Boston, focusing on clinical trial management. CEO Jeffrey Meckler highlighted the importance of this recognition for the company's clinical trial management approach. The CMO Summit 360° is a major event for biotech Chief Medical Officers to share insights on efficient medicine development. Indaptus is known for its innovative therapies targeting cancer and viral infections, utilizing a unique Decoy platform that activates immune responses with reduced toxicity. The panel participation may enhance Indaptus' visibility and credibility in the biotech sector, potentially influencing its competitive positioning.

Indaptus Therapeutics, Inc. (INDP) announced new data from a weekly dosing trial of Decoy20, demonstrating successful broad activation of the immune system. The results indicate potential for Decoy20 in enhancing immune responses, which could have significant implications for cancer treatment and other immune-related conditions. Successful immune system activation data could significantly impact the company's future product development and market positioning.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) has initiated a new expansion arm in its Phase 1b/2 clinical trial to evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, focusing on safety, dosing, and preliminary anti-tumor activity in advanced solid tumors. CEO Jeffrey Meckler highlighted the potential of this combination to enhance treatment outcomes for patients. The trial will begin with Decoy20 monotherapy followed by the combination treatment, with participants receiving both therapies for up to one year or until disease progression. Indaptus aims to leverage its Decoy platform to improve immune responses against cancer, building on promising preclinical results that suggest enhanced efficacy when combined with checkpoint inhibitors. The initiation of this combination trial represents a significant strategic move that could enhance treatment options and investor sentiment.

Indaptus Therapeutics, Inc. (INDP) reported its financial results for the fourth quarter and year-end 2024, highlighting key metrics and developments. The company provided updates on its strategic initiatives and future plans, emphasizing its commitment to advancing its therapeutic pipeline and enhancing shareholder value. Financial results and strategic updates indicate a moderate influence on the company's future performance and market positioning.

Indaptus Therapeutics, Inc. has expanded its patent portfolio in China, Japan, and Israel, enhancing its intellectual property related to treatments for infectious diseases and cancer. This strategic move aims to strengthen the company's competitive position in these key markets. Expanding the patent portfolio in multiple countries is likely to significantly enhance the company's market position and investor sentiment.

Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced that Chief Scientific Officer Dr. Michael Newman will present at the 10th Annual Innate Killer Summit in San Diego from March 3-5, 2025. His presentation will cover the Decoy platform, which aims to activate innate and adaptive immune responses against tumors, and will include clinical data from an ongoing Phase 1 trial of Decoy20 for advanced solid tumors. CEO Jeffrey Meckler expressed excitement about sharing progress in immune-based therapies. Indaptus focuses on developing treatments for cancer and viral infections using a novel approach involving non-pathogenic Gram-negative bacteria. The presentation at a major conference and the ongoing clinical trial could significantly influence investor sentiment and the company's strategic direction.

Indaptus Therapeutics, Inc. has received Clinical Trial Authorization from Health Canada to expand its clinical trial for Decoy20 into Canadian sites, enhancing patient recruitment and clinical research. The trial will continue with weekly dosing of Decoy20, and an amendment will be submitted to include a combination trial with tislelizumab. CEO Jeffrey Meckler emphasized the importance of this expansion for gathering diverse data, while CMO Roger Waltzman noted it will accelerate clinical data collection and improve treatment outcomes for patients with solid tumors. Expanding clinical trials to Canada and incorporating combination therapies could significantly enhance data collection and treatment efficacy, impacting future product development and market positioning.

Indaptus Therapeutics, Inc. has announced a private placement of $2.25 million, priced at-the-market under Nasdaq rules. The offering is expected to enhance the company's financial position and support its ongoing development initiatives. The private placement is likely to provide necessary funding for development, impacting financial performance moderately.

Indaptus Therapeutics, Inc. (INDP) provided a year-end review highlighting its achievements and outlining strategic goals for 2025. The company emphasized advancements in its therapeutic pipeline and plans for upcoming clinical trials. Financial performance metrics were discussed, showcasing growth and investment in research and development. The outlook for 2025 includes expectations for further progress in product development and potential partnerships to enhance market presence. Significant strategic goals and advancements in the therapeutic pipeline are likely to impact future performance and investor sentiment.

Indaptus Therapeutics, Inc. announces a $2.135 million registered direct offering and concurrent private placement. The offering is expected to have a significant impact on the company's future financial position and research and development activities.

Indaptus Therapeutics published groundbreaking research on novel immunotherapy approach in Frontiers in Immunology, showcasing potential of Decoy platform to enhance cancer treatment. The publication of innovative research and potential collaboration with BeiGene for combination therapy indicates a significant impact on Indaptus Therapeutics' future and market performance.

Indaptus Therapeutics presented encouraging interim safety data from Phase 1 clinical trial of Decoy20 at SITC 2024 Annual Meeting. The positive safety data from the Phase 1 trial could lead to significant advancements in Indaptus Therapeutics' product development and market positioning.

Indaptus Therapeutics, Inc. (INDP) CEO to present at two upcoming investor conferences in New York City. The presentation at investor conferences could lead to significant impact on future performance and market sentiment.

Indaptus Therapeutics announces clinical supply agreement with BeiGene to evaluate novel cancer treatment combinations. The agreement with BeiGene for a clinical trial combining Decoy20 with tislelizumab could significantly impact Indaptus' future cancer treatment outcomes and market positioning.

Indaptus Therapeutics initiates unrestricted enrollment of patients on Decoy20 weekly dosing based on encouraging safety data. The unrestricted enrollment of patients at the lower Decoy20 dose and the potential for combination therapy studies could significantly impact the future and performance of Indaptus Therapeutics.